Boehringer Ingelheim Corporation Release: GIOTRIF® (afatinib)* Approved in Europe for Patients With EGFR Mutation Positive Lung Cancer
9/25/2013 9:29:33 AM
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today that the European Commission has granted marketing authorisation for afatinib monotherapy, for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). Afatinib will be marketed in Europe under the brand name GIOTRIF®.
Help employers find you! Check out all the jobs and post your resume.
comments powered by